scispace - formally typeset
J

Jean Christophe Barale

Researcher at Pasteur Institute

Publications -  10
Citations -  2170

Jean Christophe Barale is an academic researcher from Pasteur Institute. The author has contributed to research in topics: Plasmodium falciparum & Artemisinin. The author has an hindex of 4, co-authored 7 publications receiving 1860 citations. Previous affiliations of Jean Christophe Barale include Centre national de la recherche scientifique & University of Paris.

Papers
More filters
Journal ArticleDOI

A Worldwide Map of Plasmodium Falciparum K13-Propeller Polymorphisms

Didier Menard, +97 more
TL;DR: In this article, the authors analyzed the K13-propeller sequence polymorphism in 14,037 samples collected in 59 countries in which malaria is endemic and identified 108 nonsynonymous K13 mutations, which showed marked geographic disparity in their frequency and distribution.
Journal ArticleDOI

CyProQuant-PCR: a real time RT-PCR technique for profiling human cytokines, based on external RNA standards, readily automatable for clinical use

TL;DR: The real-time RT-PCR technique based on a RNA standard curve, CyPro Quantitative PCR, allows for a genuine absolute quantification and a simultaneous analysis of a large panel of human cytokine mRNA and represents a potent and attractive tool for immunomonitoring.
Journal ArticleDOI

LANCL1, an erythrocyte protein recruited to the Maurer's clefts during Plasmodium falciparum development.

TL;DR: It is proposed that the interaction between PfSBP1 and LANCL1 is central for late steps of the parasite development to prevent premature rupture of the red blood cell membrane.
Journal ArticleDOI

In vitro activity of ferroquine against artemisinin-based combination therapy (ACT)-resistant Plasmodium falciparum isolates from Cambodia

TL;DR: Ferroquine exerts promising efficacy against ACT-resistant isolates, and the susceptibility range observed was in accordance with those measured in ACT resistance-free areas, which enables consideration of ferroquines as a relevant therapeutic option againstACT-resistant malaria.